case_images: PMC10666640_01
case_images: Visual analogue scale scores scaled from 1 to 10 for anorexia nervosa related items prior to, during and after the first dosing period (d - 4 to d + 18). Scores are based on the means of ratings in the morning and evening except for day 5 (morning rating only) and day 8 (evening rating only); the immediate discharge from inpatient treatment on day 5 also led to missing data for day 6 and day 7.
case_images: fpsyt-14-1267495-g001.jpg
case_images: PMC10666640_01_fpsyt-14-1267495-g001.jpg
case_images: fig1
case_images: Weight loss amounted to 15 kg 7 months after onset of EBV infection (recalled premorbid weight 69 kg), after which a body weight of around 53-55 kg was maintained for approximately 12 months (Supplementary Figure S1A). Multimodal treatment according to German treatment guidelines led to weight gain ( 1 kg/week; Supplementary Figure S1B). Similar to previous findings, daily means of VAS items revealed reductions in repetitive thoughts of food, fear of weight gain, feeling fat, inner tension, depressed mood, and urge to move (Figure 1). During the initial 11 weeks of inpatient treatment serum leptin levels proved undetectable (see Supplementary Figure S1B). BMI increased over the course of the treatment (Supplementary Figure S1B_2). BDI-II score dropped from 25 (d - 1) to 8 (day 9). BMI dropped from 18.8 kg/m2 by 0.4 kg/m2 during the dosing period but returned to the same value (18.8 kg/m2) at the end of the treatment period (Supplementary Figure S1C). The BMI development over the whole course of the treatment is shown in Supplementary Figure S1D.
case_images: Visual analogue scale scores scaled from 1 to 10 for items fatigue, sleep quality and muscle pain prior to, during and after the first dosing period (d - 4 to d + 18). Scores for fatigue are based on the means of ratings obtained mornings and evenings except for day 5 (morning rating only) and day 8 (evening rating only); sleep quality was rated once daily (1 = very good; VAS item was not scored on d - 3, day 3 and day 12). In contrast, only evening scores for muscle pain were used (morning ratings during the dosing period skewed between 2 and 4); missing data for day 5 to day 7 (see Methods).
case_images: fpsyt-14-1267495-g002.jpg
case_images: PMC10666640_01_fpsyt-14-1267495-g002.jpg
case_images: fig2
case_images: VAS items fatigue and muscle pain (evening ratings only) dropped rapidly after initiation of dosing (Figure 2). Sleep quality (scores based mainly on morning ratings) improved after initiation of dosing (Figure 2).
case_images: Visual analogue scale scores scaled from 1 to 10 for anorexia nervosa related items prior to, during and after the second dosing period (d - 1 to d + 3). Scores are based on the means of ratings in the morning and evening.
case_images: fpsyt-14-1267495-g003.jpg
case_images: PMC10666640_01_fpsyt-14-1267495-g003.jpg
case_images: fig3
case_images: After initiation of dosing all VAS items dropped rapidly during the first 5 days (see Figure 3).
case_images: Visual analogue scale scores scaled from 1 to 10 for items tiredness, sleep quality and muscle pain prior to, during and after the second dosing period (d - 1 to d + 3). Scores for fatigue are based on the means of ratings obtained mornings and evenings; sleep quality was rated once daily (1 = very good).
case_images: fpsyt-14-1267495-g004.jpg
case_images: PMC10666640_01_fpsyt-14-1267495-g004.jpg
case_images: fig4
case_images: Sleep quality, fatigue and muscle pain improved again with a fast onset (see Figure 4).